Washington Business Summer 2020 | Page 15

washington business Seahawks Announce $500,000 in Grants from Players Equality & Justice for All Action Fund The Seattle Seahawks announced in June they will give away $500,000 from the Seahawks Players Equality & Justice for All Action Fund following the “unacceptable act of violence” against George Floyd in Minneapolis and countless others who died in a similar manner. The Seahawks Players Equality & Justice for All Action Fund was created in 2017 as a way for Seahawks players to help “create lasting change and build a more compassionate and inclusive society.” The recipients of the $500,000 grants have not been decided, but the team said they “hope to advance conversations related to reformation in our nation’s current policies regarding hiring and training within law enforcement, judiciary protections and accountability, and for advanced education related to the history of race in America.” In a separate statement, quarterback Russell Wilson said “We cannot continue to ignore racism as though it has ended, or never happened. The continual violence inflicted upon blacks and people of color must stop. We need change now. We need love. We need compassion. We need grace and forgiveness even in the midst of this pain. We need true leadership. We need justice. We need equality.” Seattle’s Athira Pharma Lands $85 Million in Financing for Alzheimer’s and Parkinson’s Cure Athira Pharma announced in June that it had raised $85 million in Series B financing to support its research for cures for Alzheimer’s and Parkinson’s disease. The company is entering a key phase of testing on its NDX-1017 drug, which has the potential to not only slow the progression of Alzheimer’s, but to restore brain function. “What was good for us here was that we had a really good story,” President and CEO Leen Kawas said. “We had fantastic data and a huge medical need — Alzheimer’s patients. It was very obvious that despite the macro environment changes, there is still a huge medical need in Alzheimer’s, and the intrinsic value of the work that we’re doing was still there.” The $85 million in funding, at the upper end of what it had hoped for, will enable more comprehensive trials, a doubling of its 17-employee staff, and work on other of its less-developed drug candidates. AWB featured the company (then known as M3 Biotechnology) in our Grow Here campaign and named Kawas AWB’s inaugural Entrepreneur of the Year during the 2016 Evening of Excellence awards gala. summer 2020 15